These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 9915270)
1. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270 [TBL] [Abstract][Full Text] [Related]
2. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802 [TBL] [Abstract][Full Text] [Related]
3. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage. Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312 [TBL] [Abstract][Full Text] [Related]
4. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism. Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180 [TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Lemmilä S; Saha H; Virtanen V; Ala-Houhala I; Pasternack A Am J Nephrol; 1998; 18(5):404-10. PubMed ID: 9730564 [TBL] [Abstract][Full Text] [Related]
6. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408 [TBL] [Abstract][Full Text] [Related]
8. [Effect of calcitriol on secondary hyperparathyroidism]. Xu H; Zhang J; Cheng X; Zhou Q Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691 [TBL] [Abstract][Full Text] [Related]
9. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass. Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225 [TBL] [Abstract][Full Text] [Related]
10. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702 [TBL] [Abstract][Full Text] [Related]
11. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547 [TBL] [Abstract][Full Text] [Related]
12. Predicting the effect of intravenous calcitriol on parathyroid gland activity using double-phase technetium Tc 99m-sestamibi scintigraphy. Torregrosa JV; Fuster D; Ybarra J; Ortín J; Moreno A; Valveny N Am J Kidney Dis; 2004 Sep; 44(3):476-80. PubMed ID: 15332220 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Malberti F; Corradi B; Cosci P; Calliada F; Marcelli D; Imbasciati E Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208 [TBL] [Abstract][Full Text] [Related]
15. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539 [TBL] [Abstract][Full Text] [Related]
16. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Llach F; Yudd M Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387 [TBL] [Abstract][Full Text] [Related]
17. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405 [TBL] [Abstract][Full Text] [Related]
18. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients. Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898 [TBL] [Abstract][Full Text] [Related]
19. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416 [TBL] [Abstract][Full Text] [Related]
20. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Ardissino G; Schmitt CP; Bianchi ML; Daccò V; Claris-Appiani A; Mehls O Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]